NCT00744562 - A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

November 30, 2011

Study Completion Date

January 31, 2012

Conditions

Solid Tumors

Interventions

DRUG

OMP-21M18

0.5, 1, 2.5, 5, and 10 mg/kg weekly until day 56. If patient has not progressed may continue with original dose administered every other week until progression

Trial Locations (3)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

94305

Stanford University, Stanford

94904

California Cancer Care, Greenbrae